FINWIRES · TerminalLIVE
FINWIRES

在高油價背景下,瑞銀更新了其加拿大宏觀經濟預測

-- 瑞銀表示,已將油價的最新走勢納入其對加拿大通膨的預測,並採用了原油期貨暗示的最新路徑:布蘭特原油5月合約價格將達到每桶118美元,預計到年底將穩定在每桶78美元左右,到2027年底將穩定在每桶73美元左右。 基於此,瑞銀目前預估今年加拿大整體通膨率為2.9%,2027年為2.4%。瑞銀預計3月加拿大整體通膨率將強勁上漲1.3%(未季節性調整),使年比通膨率在3月上升1個百分點至2.8%。 瑞銀預測,整體通膨率將在4月達到高峰3.4%,之後將回落。 在瑞銀的成長預測中,預計出口成長將加快,但下調了企業固定投資和消費預期。 整體而言,該行的年度預測變化不大,預計今年年增長率為1.6%,2027年為1.7%。 最新的月度國內生產毛額(GDP)數據顯示,今年開局尚可,1月份GDP環比增長0.1%,略優於此前預估的持平數據;2月份的預估環比增長0.2%。 繼2月就業人數全面大幅下降之後,瑞銀預測3月就業人數將溫和成長1.6萬人,預計週五公佈的就業數據顯示,失業率將維持在6.7%不變。

Related Articles

Asia

National Australia Bank Shares Down After Resolution of Union Court Proceedings

National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."

$ASX:NAB
Asia

Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant

Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.

$ASX:CUV
Asia

XRF Scientific Completes Acquisition of Combustion Gas Analysis Business

XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.

$ASX:XRF